Pharmacy Times July 3, 2025
Expert explores the expanding role of FDA-approved Prescription Digital Therapeutics (PDTs).
In an interview with Pharmacy Times®, Areo Nazari, PharmD, CEO at CaryHealth, discussed how prescription digital therapeutics (PDTs) are FDA-approved, software-based treatments that offer alternatives or complements to traditional therapies. He emphasized that broader access—particularly through CMS coverage—is crucial for their growth and acceptance. Nazari highlighted the importance of a seamless digital infrastructure for onboarding, educating, and delivering PDTs to patients. He also noted that pharmacists will play a key role in supporting digital prescriptions and engaging in Remote Therapeutic Monitoring (RTM).
Pharmacy Times: Can you give a brief overview of PDTs?
Areo Nazari, PharmD: PDTs are digital or software-based treatments that are approved by the FDA to treat...
Today's Sponsors
Today's Sponsor